Epoch Investment Partners Inc. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 9.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,214 shares of the medical research company’s stock after selling 4,505 shares during the period. Epoch Investment Partners Inc.’s holdings in Thermo Fisher Scientific were worth $22,224,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC increased its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $170,000. Raymond James Financial Inc. increased its holdings in shares of Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after acquiring an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after purchasing an additional 2,262 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Thermo Fisher Scientific
Key Headlines Impacting Thermo Fisher Scientific
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
- Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
- Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
- Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
- Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article
Thermo Fisher Scientific Stock Performance
NYSE TMO opened at $567.34 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market cap of $210.83 billion, a P/E ratio of 30.52, a PEG ratio of 2.49 and a beta of 0.87. The company’s 50-day simple moving average is $494.01 and its 200 day simple moving average is $513.46.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
